
|Articles|January 1, 2008 (Updated: November 10, 2020)
Oncology NEWS International
- Oncology NEWS International Vol 17 No 1
- Volume 17
- Issue 1
Sunesis and MMRC collaborate to study SNS-032 in myeloma
Sunesis and MMRC collaborate to study SNS-032 in myeloma
Advertisement
SOUTH SAN FRANCISCO, California-Sunesis Pharmaceuticals, Inc. and the Multiple Myeloma Research Consortium (MMRC) have entered into a collaboration to evaluate Sunesis' SNS-032 for the treatment of multiple myeloma. SNS-032 is a potent, selective inhibitor of cyclin-dependent kinases (CDKs) 2, 7, and 9 that inhibits both cell cycle progression and transcription.
Articles in this issue
about 18 years ago
New tobacco product alert: Camel Snus is on the looseabout 18 years ago
Blueberry punch not quite a 'knock out' blowabout 18 years ago
Texas voters listen to Lanceabout 18 years ago
Cellectar opens manufacturing facility for radiolabeled CLR1404about 18 years ago
High cost of breast MRI screening appears to be justifiedabout 18 years ago
Broccoli Sprouts Extract Might Lower Bladder Cancer Riskabout 18 years ago
Xeloda/Ixempra Effective in Resistant Triple-Negative Caabout 18 years ago
Statins during RT may lower risk of prostate ca relapseNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement


Will the FDA Approve Iberdomide in Relapsed/Refractory Multiple Myeloma?
Published: | Updated:



Advertisement
Advertisement
Trending on CancerNetwork
1
Dato-DXd/Durvalumab Shows Promising Outcomes in Advanced TNBC
2
GLP-1 Receptor Agonists in Breast Cancer: 5 Key Clinical Takeaways
3
Ultra-Hypofractionation Proves Feasible in Locally Advanced Breast Cancer
4
What Were the Top 2026 ACSO Genitourinary Symposium Abstracts?
5



















































